Skip to content

A Blended Intervention to Promote Physical Activity, Health and Work Productivity Among Office Employees

A Blended Intervention to Promote Physical Activity, Health and Work Productivity Among Office Employees Using Intervention Mapping: A Study Protocol for a Randomized Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04391270
Enrollment
141
Registered
2020-05-18
Start date
2022-09-01
Completion date
2023-07-30
Last updated
2024-03-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Physically Well But Worried

Keywords

physical activity, health promotion

Brief summary

The primary objective of this study is to examine between-group differences in changes of objectively measured MVPA levels (min/week) among a randomly selected sample of office employees who are physically inactive in Hong Kong.

Detailed description

Regular participation in moderate-to-vigorous physical activity (MVPA) is related to decreased risk of morbidity and mortality. Among working populations, lack of MVPA may also be a risk factor for absenteeism and presenteeism. Both traditional workplace-based and web-based interventions have been suggested as being effective in promoting participation MVPA, health-related outcomes, and work-related productivity. However, several challenges limit their application in real world contexts. A 'blended' intervention approach combining the two intervention strategies is proposed to overcome these limitations. The proposed intervention aims to utilize the blended approach to increase participation in MVPA, health-related outcomes, and work productivity among inactive workers. Methods: The study will comprise of a three group cluster randomized controlled trial (cluster-RCT), comprising a three-month actual intervention and a nine-month behavioral follow-up period. The three groups will be: a web-based intervention group, a blended intervention group combining the web-based components with face-to-face workshops, and a control group. Physically inactive office employees (N = 141) from will be recruited and randomly assigned to the three groups by cluster randomization. The intervention mapping (IM) framework will be used for selecting and applying effective health behavioural theories and behavioural change techniques (BCTs) to the development, implementation and assessment of the intervention, which will be personally tailored. The primary outcome variable will be objectively measured MVPA using an accelerometer. Secondary outcomes will consist of indices of health including adiposity, blood pressure, blood sugar, blood lipids, self-reported depression, anxiety, stress, and health-related quality of life, and work-related variables including absenteeism and presenteeism.

Interventions

A blended intervention group combining the web-based components with face-to-face workshops and posters

A web-based intervention only referred to the use of internet without traditional face-to-face workshops and posters

Sponsors

Hong Kong Baptist University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* physically inactive (do NOT meet the WHO's recommended MVPA levels) * office employees in Hong Kong.

Exclusion criteria

* participants are engaging other ongoing programs involving MVPA promotion * if they report any conditions preventing them from being active.

Design outcomes

Primary

MeasureTime frameDescription
moderate-to-vigorous physical activity (MVPA) levelsbaseline, 13 weeks, 25 weeksexamine between-group differences in changes of objectively measured MVPA levels (min/week) among a randomly selected sample of office employees who are physically inactive in Hong Kong

Secondary

MeasureTime frameDescription
Height in metersbaseline, 13 weeks, 25 weeksHeight will be measured to the nearest 0.1 cm using a stadiometer.
Weight in kilogramsbaseline, 13 weeks, 25 weeksWeight will be measured to the nearest 0.1 kg on a calibrated digital balance scale (Seca, max. 200 kg, Germany) with the participants wearing lightweight clothing and no shoes.
Body mass index (BMI, kg/m2)baseline, 13 weeks, 25 weeksBody mass index (BMI, kg/m2) will be calculated from weight and height.
Waist circumference (cm)baseline, 13 weeks, 25 weeksWaist circumference (cm) will be measured midway between the lowest rib margin and the top of the iliac crest at the end of gentle expiration
%Body fatbaseline, 13 weeks, 25 weeks%BF will be assessed by a Tanita TBF-410 Body Composition Analyzer (Tanita Corporation, Tokyo, Japan) using foot-to-foot bioelectrical impedance analysis (BIA).
changes of self-report MVPA levels (min/week)baseline, 13 weeks, 25 weeksTo examine between-group differences in changes of self-reported MVPA levels (min/week) in different domains among the sample.
Hemoglobin A1C (%)baseline, 13 weeks, 25 weeksHemoglobin A1C will be measured using the Reflotron ® Plus system (Roche Diagnostics, F. Hoffmann-La Roche Ltd., Burgess Hill, UK).
Depression, anxiety and stressbaseline, 13 weeks, 25 weeksDepression, anxiety and stress will be measured using the Chinese version of the Depression Anxiety Stress Scale (DASS-21)
Presenteeismbaseline, 13 weeks, 25 weeksIt will be assessed using presenteeism questions derived from the WHO's Heath and Work Performance Questionnaire (HPO).
High-density lipoprotein (mmol/L)baseline, 13 weeks, 25 weekshigh-density lipoprotein will be measured using the Reflotron ® Plus system (Roche Diagnostics, F. Hoffmann-La Roche Ltd., Burgess Hill, UK).
Triglyceride (mmol/L)baseline, 13 weeks, 25 weeksTriglyceride will be measured using the Reflotron ® Plus system (Roche Diagnostics, F. Hoffmann-La Roche Ltd., Burgess Hill, UK).
Blood pressure (mmHg)baseline, 13 weeks, 25 weeksBlood pressure will be measured using the Omron M6 Compact (HEM-7000-E, Omron Healthcare Corporation, Kyoto, Japan) following standard measurement protocols.

Countries

Hong Kong

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 27, 2026